DarioHealth Corp. (NASDAQ:DRIO) Receives Average Rating of “Hold” from Brokerages

DarioHealth Corp. (NASDAQ:DRIO) has been given a consensus recommendation of “Hold” by the five research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $32.00.

DRIO has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DarioHealth in a research note on Wednesday, October 8th. Cowen restated a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Wall Street Zen raised DarioHealth from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Stifel Nicolaus set a $16.00 price target on shares of DarioHealth in a research report on Friday, November 14th.

Hedge Funds Weigh In On DarioHealth

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd grew its position in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 62,511 shares of the company’s stock after buying an additional 43,513 shares during the period. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 at the end of the most recent quarter. 33.39% of the stock is currently owned by hedge funds and other institutional investors.

DarioHealth Price Performance

Shares of DRIO stock opened at $12.15 on Tuesday. The firm’s 50 day moving average price is $13.80 and its two-hundred day moving average price is $12.53. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55. DarioHealth has a 52-week low of $5.93 and a 52-week high of $31.00. The stock has a market cap of $82.23 million, a PE ratio of -1.09 and a beta of 1.08.

DarioHealth Company Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.